Issn Print: 0027-8874
Publication Date: 2017/11/01
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais; Barbara Mueller; Mark F. Brady; Robert S. Mannel; Robert A. Burger; Wei Wei; Koen M. Marien; Mark M. Kockx; Amreen Husain; Michael J. Birrer
Author Information: Genentech Inc., South San Francisco, CA (CB – affiliation when this work was performed, AH); F Hoffmann-La Roche Ltd, Basel, Switzerland (BM); NRG Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY (MFB); University of Oklahoma, Oklahoma City, OK (RSM); Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA (RAB); Center for Cancer Research, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (WW, MJB); HistoGeneX NV, Antwerp, Belgium (KMM, MMK); Division of Physiopharmacology, University of Antwerp, Antwerp, Belgium (KMM).
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.